What You Should Know:
COTA, Inc., an oncology real-world data and analytics company announced a partnership with Google Cloud to bring clarity to unstructured oncology data through the latest advancements in machine learning and natural language processing.
- Many leading real-world data companies - including COTA - leverage clinicians to manually curate oncology real-world data. While this is a reliable and trusted near-term solution to overcoming the challenges associated with
Read More
Cancer | Digital Health Impact on Cancer Care | Policy, News, Analysis, Insights - HIT Consultant
18 HLTH 2022 Predictions from Digital Health Executives to Watch
Before HLTH 2022 kicks off next week in Las Vegas, we asked 18 digital health executives for their predictions and major themes to expect at HLTH.
1. Keith Reynolds, Chief Operating Officer at Welldoc
Access to care is a central focus for healthcare given several factors: a growing population being impacted with chronic conditions, increased resourcing constraints, and growing fatigue and workload among providers. A recent study indicated that it would require a PCP 26.7 hours/ day
Read More
AI ‘s Role in Drug Discovery: Separating the Hype from the Hope
Forecasting the influence that artificial intelligence (AI)/machine learning technologies will have on the future of healthcare has created a cottage industry in the hype. From the overzealous aspirations of IBM’s Watson Health initiative to the inclusion of AI on Gartner’s 2021 Hype Cycle at the “Peak of Inflated Expectations,” so much noise has been made around AI/machine learning in healthcare that it can be difficult to appreciate the current impact of these technologies on drug discovery,
Read More
JPMorgan Establishes Life Sciences Private Equity Division
What You Should Know:
- J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital.
- The new team will focus on investing in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity,
Read More
Research: Proscia AI Predicts Diagnostic Agreement for Melanoma
What You Should Know:
- Proscia® a provider of digital and computational pathology solutions, has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.
- The findings, which were presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.
Findings
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know:
- Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records.
- Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
Overcoming Ripple Effects of COVID-19 to Boost Patient Outcomes: 3 Insights
Fear of COVID-19 exposure isn’t the only thing holding patients back from seeking needed care during the pandemic. So are the complexities of navigating life after COVID-19—and it’s a struggle that physicians, who are overworked and burned out, can relate to as well.
Even as data indicates that consumer deferment of care—common during the first 18 months of the pandemic—has decreased, not all consumers have returned for care as soon as expected. In some instances, financial concerns
Read More
The Gains and Pains of Using AI in the Pharmaceutical Industry
The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster.
A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million. Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most
Read More
COTA Secures New Financing to Accelerate Cancer Research and Treatment Innovation
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management and additional capital from existing investors.
- The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drug development in oncology.
- Perella Weinberg Partners LP served as exclusive financial advisor and Goodwin Procter
Read More
Moving The Focus of Healthcare to Building Healthy Habits That Last
Without addressing root causes through sustained behavior modification, all results are temporary
The most effective approach to preventing and treating chronic disease today focuses on the creation of healthy habits that fundamentally change behavior in a sustainable way. Smart solutions involve personalized programs based on genetic testing, nutrition, exercise, mental well-being and 1:1 personal health coaching. This combination has achieved remarkable success in both warding off chronic
Read More
